This Unmet Need report focuses on the treatment of previously treated RAS and BRAF mutation-positive metastatic colorectal cancer. Currently, the NCCN guidelines and treatment practices for metastatic colorectal cancer include the determination of tumor gene status for RAS (KRAS / NRAS) and BRAF mutation-positive patients. In second- and later-line settings, RAS and BRAF mutation-positive patients are treated with anti-VEGF therapies, such as Avastin (Genentech/Roche), Cyramza (Eli Lilly), Stivarga (Bayer), and Zaltrap (Sanofi / Regeneron), with or without chemotherapy. The novel treatment regimen, consisting of BRAF + MEK inhibitors, Braftovi + Mektovi (Pfizer / Array BioPharma), in combination with the anti-EGFR therapies Erbitux (Eli Lilly / Merck KGaA) or Vectibix (Amgen), is recommended for the subsequent treatment of BRAF mutation-positive patients. Nevertheless, less-toxic, more-efficacious therapies are needed for the subsequent treatment of these two colorectal cancer subpopulations.
- What are the treatment drivers and goals for previously treated RAS / BRAF mutation-positive metastatic colorectal cancer?
- What drug attributes are key influences, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for previously treated RAS / BRAF mutation-positive metastatic colorectal cancer?
- What are the prevailing areas of unmet need and opportunity in previously treated RAS / BRAF mutation-positive metastatic colorectal cancer?
- What trade-offs across different clinical attributes and prices are acceptable to U.S. and European medical oncologists for a hypothetical new RAS / BRAF mutation-positive metastatic colorectal cancer drug?
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 32 European medical oncologists fielded in April 2020
Key companies: Pfizer / Array BioPharma, Eli Lilly / Merck KGaA, Amgen, Roche / Genentech, Bayer, Taiho Pharmaceutical
Key drugs: Braftovi, Erbitux, Vectibix, Avastin, Cyramza, Stivarga, Lonsurf
- Colorectal Cancer - Unmet Need - Detailed, Expanded Analysis (US/EU) Previously Treated RAS And BRAF Mutation-Positive Metastatic Colorectal Cancer
Author(s): Liseth Parra
Liseth M Parra, Ph.D., is an analyst on the Oncology team at Decision Resources Group with an extensive background in oncology research and market analysis. Prior to joining DRG, Liseth generated valuable offerings and comprehensive strategic solutions for leading R&D clinical, commercial, and marketing teams in oncology as a research analyst for Kantar Health and as an independent consultant. Liseth holds a Ph.D. in neurobiology from the University of California, San Diego and completed a postdoctoral fellowship in oncology at the Brigham and Women’s Hospital, Harvard Medical School. Liseth supports DRG’s syndicated oncology research offerings, focusing on malignant melanoma disease landscape and forecast analysis.